Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
Trial details
- Registry ID
- NCT06087276
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)NCT06087276 | Praxis Precision Medicines | Phase 3 | Recruiting | 2025-10-10Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |